| Immune Design is a late-stage immunotherapy company. Co. is focused on oncology and has designed its technologies to activate the immune system's ability to create tumor-specific cytotoxic T cells to fight cancer via distinct mechanisms. Co.'s primary product candidates are CMB305 and G100. CMB305 is a prime-boost cancer vaccine targeting the NY-ESO-1 tumor antigen, in which a prime called LV305 from Co.'s ZVex® platform is dosed sequentially with a boost from Co.'s GLAAS® platform. G100 activates both innate and adaptive immunity in the tumor microenvironment, including dendritic cells, to create an immune response against the tumor's set of antigens, including neoantigens. We show 20 historical shares outstanding datapoints in our IMDZ shares outstanding history coverage, used to compute IMDZ market cap on those dates.|
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing IMDZ market cap history over the course of time is important for investors
interested in comparing IMDZ's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of IMDZ versus a peer is one thing; comparing
IMDZ market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like IMDZ can fluctuate over the course of history.
With this page we aim to empower investors researching IMDZ by allowing them to research the IMDZ market cap history.